Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T

Fons Windhausen, Alexander Hirsch, Johan Fischer, P. Marc Van Der Zee, Gerard T. Sanders, Jan P. Van Straalen, Jan Hein Cornel, Jan G.P. Tijssen, Freek W.A. Verheugt, Robbert J. De Winter

Research output: Contribution to journalArticleAcademicpeer-review

41 Citations (Scopus)


BACKGROUND: We assessed the value of cystatin C for improvement of risk stratification in patients with non-ST elevation acute coronary syndrome (nSTE-ACS) and increased cardiac troponin T (cTnT), and we compared the long-term effects of an early invasive treatment strategy (EIS) with a selective invasive treatment strategy (SIS) with regard to renal function. METHODS: Patients (n = 1128) randomized to an EIS or an SIS in the ICTUS trial were stratified according to the tertiles of the cystatin C concentration at baseline. The end points were death within 4 years and spontaneous myocardial infarction (MI) within 3 years. RESULTS: Mortality was 3.4%, 6.2%, and 13.5% in the first, second, and third tertiles, respectively, of cystatin C concentration (log-rank P < 0.001), and the respective rates of spontaneous MI were 5.5%, 7.5%, and 9.8% (log-rank P = 0.03). In amultivariate Cox regression analysis, the cystatin C concentration in the third quartile remained independently predictive of mortality [hazard ratio (HR), 2.04; 95% CI, 1.02-4.10; P = 0.04] and spontaneous MI (HR, 1.95; 95% CI, 1.05-3.63; P = 0.04). The mortality rate in the second tertile was lower with the EIS than with the SIS (3.8% vs 8.7%). In the third tertile, the mortality rates with the EIS and the SIS were, respectively, 15.0% and 12.2% (P for interaction = 0.04). Rates of spontaneous MI were similar for the EIS and the SIS within cystatin C tertiles (P for interaction = 0.22). CONCLUSIONS: In patients with nSTE-ACS and an increased cTnT concentration, mild to moderate renal dysfunction is associated with a higher risk of death and spontaneous MI. Use of cystatin C as a serum marker of renal function may improve risk stratification.

Original languageEnglish
Pages (from-to)1118-1125
Number of pages8
JournalClinical Chemistry
Issue number6
Publication statusPublished - 1 Jun 2009
Externally publishedYes

Bibliographical note

© 2009 American Association for Clinical Chemistry


Dive into the research topics of 'Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T'. Together they form a unique fingerprint.

Cite this